Drugs@FDA: FDA-Approved Drugs
Abbreviated New Drug Application (ANDA): 202473
Company: MYLAN PHARMS INC
Company: MYLAN PHARMS INC
| Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
|---|---|---|---|---|---|---|---|
| SITAGLIPTIN PHOSPHATE | SITAGLIPTIN PHOSPHATE | EQ 25MG BASE | TABLET; ORAL | None (Tentative Approval) | None | No | No |
| SITAGLIPTIN PHOSPHATE | SITAGLIPTIN PHOSPHATE | EQ 50MG BASE | TABLET; ORAL | None (Tentative Approval) | None | No | No |
| SITAGLIPTIN PHOSPHATE | SITAGLIPTIN PHOSPHATE | EQ 100MG BASE | TABLET; ORAL | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
| Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
|---|---|---|---|---|---|---|---|
| 10/10/2012 | ORIG-1 | Tentative Approval |
Label is not available on this site. |